Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Research article

Identification of PIK3CA multigene mutation patterns associated with superior prognosis in stomach cancer

Authors: Yu Yu, Zhuoming Xie, Mingxin Zhao, Xiaohua Lian

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

PIK3CA is the second most frequently mutated gene in cancers and is extensively studied for its role in promoting cancer cell resistance to chemotherapy or targeted therapy. However, PIK3CA functions have mostly been investigated at a lower-order genetic level, and therapeutic strategies targeting PIK3CA mutations have limited effects. Here, we explore crucial factors interacting with PIK3CA mutations to facilitate a significant marginal survival effect at the higher-order level and identify therapeutic strategies based on these marginal factors.

Methods

Mutations in stomach adenocarcinoma (STAD), breast adenocarcinoma (BRCA), and colon adenocarcinoma (COAD) samples from The Cancer Genome Atlas (TCGA) database were top-selected and combined for Cox proportional-hazards model analysis to calculate hazard ratios of mutation combinations according to overall survival data and define criteria to acquire mutation combinations with considerable marginal effects. We next analyzed the PIK3CA + HMCN1 + LRP1B mutation combination with marginal effects in STAD patients by Kaplan-Meier, transcriptomic differential, and KEGG integrated pathway enrichment analyses. Lastly, we adopted a connectivity map (CMap) to find potentially useful drugs specifically targeting LRP1B mutation in STAD patients.

Results

Factors interacting with PIK3CA mutations in a higher-order manner significantly influenced patient cohort survival curves (hazard ratio (HR) = 2.93, p-value = 2.63 × 10^− 6). Moreover, PIK3CA mutations interacting with higher-order combination elements distinctly differentiated survival curves, with or without a marginal factor (HR = 0.26, p-value = 6.18 × 10^− 8).

Approximately 3238 PIK3CA-specific higher-order mutational combinations producing marginal survival effects were obtained. In STAD patients, PIK3CA + HMCN1 mutation yielded a substantial beneficial survival effect by interacting with LRP1B (HR = 3.78 × 10^− 8, p-value = 0.0361) and AHNAK2 (HR = 3.86 × 10^− 8, p-value = 0.0493) mutations. We next identified 208 differentially expressed genes (DEGs) induced by PIK3CA + HMCN1 compared with LRP1B mutation and mapped them to specific KEGG modules. Finally, small-molecule drugs such as geldanamycin (connectivity score = − 0.4011) and vemurafenib (connectivity score = − 0.4488) were selected as optimal therapeutic agents for targeting the STAD subtype with LRP1B mutation.

Conclusions

Overall, PIK3CA-induced marginal survival effects need to be analyzed. We established a framework to systematically identify crucial factors responsible for marginal survival effects, analyzed mechanisms underlying marginal effects, and identified related drugs.

Available only for authorised users

Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495–501. https://doi.org/10.1038/nature12912.CrossRefPubMedPubMedCentral

Vogt PK, Kang S, Elsliger MA, Gymnopoulos M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci. 2007;32(7):342–9. https://doi.org/10.1016/j.tibs.2007.05.005.CrossRefPubMed

Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, et al. PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 2008;68(19):8127–36. https://doi.org/10.1158/0008-5472.CAN-08-0755.CrossRefPubMed

Alqahtani A, Ayesh HSK, Halawani H. PIK3CA gene mutations in solid malignancies: association with clinicopathological parameters and prognosis. Cancers. 2020;12.

Arafeh R, Samuels Y. PIK3CA in cancer: the past 30 years. Semin Cancer Biol. 2019;59:36–49. https://doi.org/10.1016/j.semcancer.2019.02.002.CrossRefPubMed

Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4):605–35. https://doi.org/10.1016/j.cell.2017.07.029.CrossRefPubMedPubMedCentral

Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7–24. https://doi.org/10.1038/nrc3860.CrossRefPubMedPubMedCentral

Thang ND, Yajima I, Kumasaka MY, Iida M, Suzuki T, Kato M. Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway. Oncotarget. 2015;6(16):14290–9. https://doi.org/10.18632/oncotarget.3742.CrossRefPubMedPubMedCentral

Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4(4):257–62. https://doi.org/10.1016/S1535-6108(03)00248-4.CrossRefPubMed

10.

Foukas LC, Bilanges B, Bettedi L, Pearce W, Ali K, Sancho S, et al. Long-term p110α PI3K inactivation exerts a beneficial effect on metabolism. EMBO Mol Med. 2013;5(4):563–71. https://doi.org/10.1002/emmm.201201953.CrossRefPubMedPubMedCentral

11.

Hoxhaj G, Manning BD. The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74–88. https://doi.org/10.1038/s41568-019-0216-7.CrossRefPubMed

12.

Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol Med. 2018;24(10):856–70. https://doi.org/10.1016/j.molmed.2018.08.003.CrossRefPubMedPubMedCentral

13.

Ito C, Nishizuka SS, Ishida K, Uesugi N, Sugai T, Tamura G, et al. Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer. J Surg Res. 2017;212:195–204. https://doi.org/10.1016/j.jss.2017.01.018.CrossRefPubMed

14.

Ye B, Jiang LL, Xu HT, Zhou DW, Li ZS. Expression of pi3k/akt pathway in gastric cancerand its blockade suppresses tumor growth and metastasis. Int J Immunopathol Pharmacol. 2012;25(3):627–36. https://doi.org/10.1177/039463201202500309.CrossRefPubMed

15.

Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatology Research. 2009;39(2):177–186. https://doi.org/10.1111/j.1872-034X.2008.00449.x

16.

Res H. 2009;39:177–86.Huang T, Liu D, Wang Y, Li P, Sun L, Xiong H, et al. FGFR2 promotes gastric Cancer progression by inhibiting the expression of Thrombospondin4 via PI3K-Akt-Mtor pathway. Cell Physiol Biochem. 2018;50:1332–45.CrossRef

17.

Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003;2(4):336–42. https://doi.org/10.4161/cc.2.4.433.CrossRef

18.

Payne SN, Maher ME, Tran NH, Van De Hey DR, Foley TM, Yueh AE, et al. PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis. 2015;4(10):e169. https://doi.org/10.1038/oncsis.2015.28.CrossRefPubMedPubMedCentral

19.

Sheen MR, Marotti JD, Allegrezza MJ, Rutkowski M, Conejo-Garcia JR, Fiering S. Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis. 2016;5(10):e267. https://doi.org/10.1038/oncsis.2016.65.CrossRefPubMedPubMedCentral

20.

Torgerson DJ, Spencer A. Marginal costs and benefits. Br Med J. 1996;312(7022):35–6. https://doi.org/10.1136/bmj.312.7022.35.CrossRef

21.

Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–56. https://doi.org/10.1101/gr.239244.118.CrossRefPubMedPubMedCentral

22.

Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 2017;171:1437–52.e17.CrossRef

23.

Lu YJ, Wu CS, Li HP, Liu HP, Lu CY, Leu YW, et al. Aberrant methylation impairs low density lipoprotein receptor-related protein IB tumor suppressor function in gastric cancer. Genes Chromosom Cancer. 2010;49(5):412–24. https://doi.org/10.1002/gcc.20752.CrossRefPubMed

24.

Hurt EM, Chan K, Serrat MAD, Thomas SB, Veenstra TD, Farrar WL. Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation. Stem Cells. 2010;28(3):390–8. https://doi.org/10.1002/stem.271.CrossRefPubMedPubMedCentral

25.

Thiers BH. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Yearb Dermatology Dermatologic Surg. 2007;2007:384–6.

26.

Lian L, Li XL, Xu MD, Li XM, Wu MY, Zhang Y, et al. VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer. BMC Cancer. 2019;19:479–89.CrossRef

27.

Ouyang Q, Gong X, Xiao H, Zhou J, Xu M, Dai Y, et al. Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients. Mol Cancer. 2015;14(1):21. https://doi.org/10.1186/s12943-015-0290-8.CrossRefPubMedPubMedCentral

28.

Wang W, Shen T, Dong B, Creighton CJ, Meng Y, Zhou W, et al. MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling. J Clin Invest. 2019;129(3):1015–29. https://doi.org/10.1172/JCI97712.CrossRefPubMedPubMedCentral

29.

Wang J, Huff AM, Spence JD, Hegele RA. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration. Clin Genet. 2004;65(6):483–6. https://doi.org/10.1111/j.1399-0004.2004.00250.x.CrossRefPubMed

30.

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16. https://doi.org/10.1056/NEJMoa1103782.CrossRefPubMedPubMedCentral

31.

Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell. 1997;89(2):239–50. https://doi.org/10.1016/S0092-8674(00)80203-2.CrossRefPubMed

32.

Zhao X, Lang L, He L, Gao L, Chyan D, Xiong Y, et al. Intracellular reduction in ATP levels contributes to CYT997-induced suppression of metastasis of head and neck squamous carcinoma. J Cell Mol Med. 2019;23(2):1174–82. https://doi.org/10.1111/jcmm.14017.CrossRefPubMed

33.

Zhang L, Yi Y, Guo Q, Sun Y, Ma S, Xiao S, et al. Hsp90 interacts with AMPK and mediates acetyl-CoA carboxylase phosphorylation. Cell Signal. 2012;24(4):859–65. https://doi.org/10.1016/j.cellsig.2011.12.001.CrossRefPubMed

34.

Baird L, Suzuki T, Takahashi Y, Hishinuma E, Saigusa D, Yamamoto M. Geldanamycin-derived HSP90 inhibitors are synthetic lethal with NRF2. Mol Cell Biol. 2020;40(22). https://doi.org/10.1128/MCB.00377-20.

35.

Mo Q, Zhang Y, Jin X, Gao Y, Wu Y, Hao X, et al. Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis. Tumor Biol. 2016;37(11):14745–55. https://doi.org/10.1007/s13277-016-5297-2.CrossRef

36.

Rimawi MF, de Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, et al. Low PETN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018;167(3):731–40. https://doi.org/10.1007/s10549-017-4533-9.CrossRefPubMed

37.

Velasco A, Bussaglia E, Pallares J, Dolcet X, Llobet D, Encinas M, et al. PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-RAS alterations. Hum Pathol. 2006;37(11):1465–72. https://doi.org/10.1016/j.humpath.2006.05.007.CrossRefPubMed

38.

Wang L, Hu H, Pan Y, Wang R, Li Y, Shen L, et al. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One. 2014;9.

39.

Kim A, Lee JE, Lee SS, Kim C, Lee SJ, Jang WS, et al. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer. Int J Cancer. 2013;133(4):984–96. https://doi.org/10.1002/ijc.28073.CrossRefPubMed

40.

L. Michmerhuizen N, Leonard E, Kulkarni A, Brenner JC. Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC. Otorhinolaryngol Neck Surg. 2016;1:44–50.CrossRef

41.

Blair BG, Bardelli A, Park BH. Somatic alterations as the basis for resistance to targeted therapies. J Pathol. 2014;232(2):244–54. https://doi.org/10.1002/path.4278.CrossRefPubMed

42.

Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017;49(12):1693–704. https://doi.org/10.1038/ng.3990.CrossRefPubMedPubMedCentral

43.

Nishii T, Yokose T, Miyagi Y, Daigo Y, Isaka T, Furumoto H, et al. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma. Asia Pac J Clin Oncol. 2017;13(5):e204–11. https://doi.org/10.1111/ajco.12512.CrossRefPubMed

Title: Identification of PIK3CA multigene mutation patterns associated with superior prognosis in stomach cancer
Authors: Yu Yu
Zhuoming Xie
Mingxin Zhao
Xiaohua Lian
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08115-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Locoregional recurrence via mucus-mediated extension following lung resection for mucinous tumors

Prediction of serosal invasion in gastric cancer: development and validation of multivariate models integrating preoperative clinicopathological features and radiographic findings based on late arterial phase CT images

Hsa_circ_0000301 facilitates the progression of cervical cancer by targeting miR-1228-3p/IRF4 Axis

COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells

LncRNA SNHG16 contributes to osteosarcoma progression by acting as a ceRNA of miR-1285-3p

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer